Precise and targeted delivery remains a significant challenge in the field of RNA therapeutics, essential for their successful clinical application. RNA molecules are inherently unstable in biological environments due to their susceptibility to degradation by RNases. To circumvent this challenge, RNA therapeutics require effective delivery systems that can protect and deliver the therapeutic RNA to its intended destination within cells. The development of innovative RNA delivery vehicles is therefore crucial. These vehicles serve multiple roles: shielding RNA from extracellular RNases, facilitating its cellular uptake, and promoting its release into the cytoplasm where it can undergo translation and produce therapeutic proteins. Various delivery strategies have been explored, including lipid nanoparticles, polymer-based carriers, viral vectors, and peptide-based complexes. Each approach offers distinct advantages in terms of stability, efficacy, and specificity in targeting different tissues or cell types. Recent advancements in RNA delivery technologies have focused on enhancing delivery efficiency, reducing immunogenicity, and improving tissue-specific targeting. Nanoparticle-based systems, for instance, can encapsulate RNA molecules, protecting them during transit through the bloodstream and enhancing their uptake by target cells through receptor-mediated endocytosis. Similarly, viral vectors engineered for RNA delivery can exploit natural mechanisms of cell entry, although concerns about safety and immune responses persist. Moreover, the ability to precisely engineer delivery systems allows for the customization of RNA therapeutics tailored to specific diseases or patient populations. This personalized approach holds promise for treating a wide range of disorders, from genetic diseases to cancers, by delivering therapeutic RNA directly to affected tissues while minimizing off-target effects. The ongoing advancements in RNA delivery systems are paving the way for the clinical translation of RNA therapeutics. By addressing the challenges of stability, delivery efficiency, and specificity, these innovations promise to unlock the full potential of RNA-based therapies in improving patient outcomes and advancing personalized medicine.